Aligos Therapeutics, Inc. (ALGS), Thursday announced an exclusive license agreement to develop and commercialize pevifoscorvir sodium with Xiamen Amoytop Biotech Co., Ltd. for chronic hepatitis B virus infection.As per the terms of the deal, Aligos will receive an upfront milestone of $25 million and is eligible to receive upto $420 million in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties on net sales in Amoytop's licensed territories.Also, Aligos will retain all ...